Novabay Pharmaceuticals Stock Today
| NBY Stock | USD 0.62 0.06 8.82% |
Performance7 of 100
| Odds Of DistressOver 75
|
NovaBay Pharmaceuticals is trading at 0.62 as of the 26th of November 2024; that is 8.82 percent decrease since the beginning of the trading day. The stock's open price was 0.68. NovaBay Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for NovaBay Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of October 2007 | Category Healthcare | Classification Health Care |
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. The company has 4.89 M outstanding shares of which 764.28 K shares are now shorted by investors with about 0.83 days to cover. More on NovaBay Pharmaceuticals
Moving against NovaBay Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NovaBay Stock Highlights
| CEO | Justin Hall | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNovaBay Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NovaBay Pharmaceuticals' financial leverage. It provides some insight into what part of NovaBay Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NovaBay Pharmaceuticals (NBY) is traded on NYSE MKT Exchange in USA. It is located in 2000 Powell Street, Emeryville, CA, United States, 94608 and employs 24 people. NovaBay Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a total capitalization of 3.33 M. NovaBay Pharmaceuticals runs under Pharmaceuticals sector within Health Care industry. The entity has 4.89 M outstanding shares of which 764.28 K shares are now shorted by investors with about 0.83 days to cover.
NovaBay Pharmaceuticals has about 5.36 M in cash with (4.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
Check NovaBay Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRoughly 97.4 % of NovaBay Pharmaceuticals outstanding shares are held by general public with 0.02 pct. owned by insiders and only 2.58 % by institutional investors.
Check NovaBay Ownership Details
NovaBay Pharmaceuticals Historical Income Statement
NovaBay Stock Against Markets
NovaBay Pharmaceuticals Corporate Executives
Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Jones | Chief Financial Officer, Treasurer | Profile |
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.